(Boursier.com) — Equasens climbed by nearly 3% this Friday, to 77.30 euros, while the group’s Q1 2022 turnover rose by 9.03% to 49.36 ME (+7% to 48.44 ME on a like-for-like basis) ). The former Pharmagest confirmed its development momentum and its growth ambitions in 2022.
The Extraordinary General Meeting of shareholders held on May 6 at the company’s registered office definitively adopted the resolution relating to the change of name to EQUASENS.
“The transition from Pharmagest to Equasens allows the Group’s identity to be better reflected in the diversity of its activities and the new markets it addresses. We are no longer just a software publisher for the pharmacy. The Group is today the leader healthcare IT solutions in Europe. For more than 10 years now, we have gone beyond the sphere of pharmacy and we equip all healthcare professionals in France and tomorrow in Europe with IT solutions. The new name and its new visual identity embody the dynamic in which the Group has resolutely entered: that of a multi-business group in Health which implements its mission of permanent analysis of the evolutions of the trades, anticipation, and development of solutions in Health with high added value and ever more interoperable” explained Thierry Chapusot, Chairman of the Board of Directors of the Equasens Group.
Outlook for the year
The group intends to maintain its growth momentum, in line with previous quarters, and confirms its ambitions for the coming months.
The referencing of its software solutions and the implementation of funding (Wave 1) of the Ségur du Numérique en Santé government program will consolidate this progress over the coming quarters and allow the group to consolidate its position as a key player in the world. of Health. Among brokers’ opinions, Portzamparc speaks of a “good start in line with its scenario”. Verdict: “Buy with a target price of 104 euros”.
©2022 Boursier.com